TABLE II.

miRNAs expression levels (copy number/μl) by demographic and clinic-pathological characteristics

Variables	N	miR-20a	miR-21	miR-145	miR-221
Age at diagnosis
< median (60 yr)	35	7,324	830	117	798
≥ median (60 yr)	47	2,978	551	108	748
p value		0.20	0.35	0.80	0.78
Ethnicity
Caucasian	46	5,175	501	95	687
African-American	10	2,368	465	90	726
Others	26	5,174	1,049	153	945
p value		0.86	0.21	0.30	0.44
Family history of prostate cancer
No	59	3,784	630	118	824
Yes	20	2,023	445	65	538
p value		0.27	0.49	0.17	0.18
Prostate volume
< median (50)	35	3,735	636	123	685
≥ median 50	36	6,806	829	128	868
p value		0.43	0.57	0.90	0.39
PSA levels (ng/ml)
< 6	51	3,850	689	109	709
≥ 6	24	7,630	748	125	955
p value		0.34	0.87	0.70	0.24
Tumor stage
T2a-T2c	63	2,908	529	103	812
≥ T3	19	11,215	1,140	145	626
p value		0.03	0.08	0.34	0.39
Gleason sum score
6	24	2,541	379	63	705
7	39	6,311	790	132	818
8–9	19	4,692	792	126	739
p value		0.63	0.45	0.21	0.86
Follow-up time (months)
< median (19.8)	38	6,141	599	106	817
≥ median (19.8)	38	2,532	495	107	686
p value		0.29	0.67	0.99	0.50
Relapse status
No	71	4,477	565	108	741
Yes	5	2,348	295	83	901
p value		0.76	0.58	0.76	0.70